This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saito, F. Articles by Tuck, M. L. Search for Related Content PubMed PubMed Citation Articles by Saito, F. Articles by Tuck, M. L.

Hypertension, Vol 20, 138-143, Copyright © 1992 by American Heart Association

ARTICLES

12-Lipoxygenase products modulate calcium signals in vascular smooth muscle cells

F Saito, MT Hori, Y Ideguchi, M Berger, M Golub, N Stern and ML Tuck
Veterans Administration Medical Center, Sepulveda, CA 91343.

Previous studies have shown that inhibition of the lipoxygenase pathway of arachidonic acid metabolism can prevent the development of elevated blood pressure in renin-dependent models of hypertension. Agents that inhibit the lipoxygenase pathway such as phenidone and the flavonoid baicalein can selectively attenuate contractile responses to angiotensin II in vivo as well as in isolated vascular tissue. In the present study, the effects of lipoxygenase inhibitors on pressor- induced changes in cytosolic calcium were examined in cultured rat vascular smooth muscle cells using the fluorescent dye fura-2. Two structurally unrelated lipoxygenase inhibitors, baicalein and 5,8,11- eicosatriynoic acid, attenuated angiotensin II-stimulated increases in cytosolic calcium in both normal and calcium-poor buffer. The addition of 5-, 12-, or 15(S)-hydroxyeicosatetraenoic acid alone to the cells had no acute effect on intracellular calcium concentration. However, the addition of 12(S)-hydroxyeicosatetraenoic acid but not 5- or 15(S)- hydroxyeicosatetraenoic acid restored the initial calcium response to angiotensin II in vascular smooth muscle cells pretreated with both inhibitors; 5,8,11-eicosatriynoic acid also reduced [Arg8]-vasopressin and endothelin-stimulated increases in intracellular calcium. The attenuation of vasopressor-induced calcium transients by agents that inhibit lipoxygenase may explain their observed hypotensive effects in vivo. Moreover, lipoxygenase products, in particular 12(S)- hydroxyeicosatetraenoic acid, may act as mediators for the intracellular actions of angiotensin II and possibly other pressor hormones in vascular tissue by regulation of intracellular calcium metabolism.

This article has been cited by other articles:

				A. Y.H. Woo, C. H.K. Cheng, and M. M.Y. Waye Baicalein protects rat cardiomyocytes from hypoxia/reoxygenation damage via a prooxidant mechanism Cardiovasc Res, January 1, 2005; 65(1): 244 - 253. [Abstract] [Full Text] [PDF]

				Y. Chen, D. Lasaitiene, B. G. Gabrielsson, L. M.S. Carlsson, H. Billig, B. Carlsson, N. Marcussen, X.-F. Sun, and P. Friberg Neonatal Losartan Treatment Suppresses Renal Expression of Molecules Involved in Cell-Cell and Cell-Matrix Interactions J. Am. Soc. Nephrol., May 1, 2004; 15(5): 1232 - 1243. [Abstract] [Full Text] [PDF]

				S. S. Yiu, X. Zhao, E. W. Inscho, and J. D. Imig 12-Hydroxyeicosatetraenoic acid participates in angiotensin II afferent arteriolar vasoconstriction by activating L-type calcium channels J. Lipid Res., December 1, 2003; 44(12): 2391 - 2399. [Abstract] [Full Text] [PDF]

				M. A. Reddy, Y.-S. Kim, L. Lanting, and R. Natarajan Reduced Growth Factor Responses in Vascular Smooth Muscle Cells Derived from 12/15-Lipoxygenase-Deficient Mice Hypertension, June 1, 2003; 41(6): 1294 - 1300. [Abstract] [Full Text] [PDF]

				R. Limor, G. Weisinger, S. Gilad, E. Knoll, O. Sharon, A. Jaffe, F. Kohen, E. Berger, B. Lifschizt-Mercer, and N. Stern A Novel Form of Platelet-Type 12-Lipoxygenase mRNA in Human Vascular Smooth Muscle Cells Hypertension, October 1, 2001; 38(4): 864 - 871. [Abstract] [Full Text] [PDF]

				S. Shastri, J. R. McNeill, T. W. Wilson, R. Poduri, C. Kaul, and V. Gopalakrishnan Cysteinyl leukotrienes mediate enhanced vasoconstriction to angiotensin II but not endothelin-1 in SHR Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H342 - H349. [Abstract] [Full Text] [PDF]

				D. Gonzalez-Nunez, J. Claria, F. Rivera, and E. Poch Increased Levels of 12(S)-HETE in Patients With Essential Hypertension Hypertension, February 1, 2001; 37(2): 334 - 338. [Abstract] [Full Text] [PDF]

				K. E. Purdy and W. J. Arendshorst Prostaglandins buffer ANG II-mediated increases in cytosolic calcium in preglomerular VSMC Am J Physiol Renal Physiol, December 1, 1999; 277(6): F850 - F858. [Abstract] [Full Text] [PDF]

				H. Takizawa, A. DelliPizzi, and A. Nasjletti Prostaglandin I2 Contributes to the Vasodepressor Effect of Baicalein in Hypertensive Rats Hypertension, March 1, 1998; 31(3): 866 - 871. [Abstract] [Full Text] [PDF]

				A. Nasjletti The Role of Eicosanoids in Angiotensin-Dependent Hypertension Hypertension, January 1, 1998; 31(1): 194 - 200. [Abstract] [Full Text] [PDF]

				E. S. Kisch, A. Jaffe, E. Knoll, and N. Stern Role of the Lipoxygenase Pathway in Angiotensin II–Induced Vasoconstriction in the Human Placenta Hypertension, March 1, 1997; 29(3): 796 - 801. [Abstract] [Full Text]

				N. Stern, E. S. Kisch, and E. Knoll Platelet Lipoxygenase in Spontaneously Hypertensive Rats Hypertension, May 1, 1996; 27(5): 1149 - 1152. [Abstract] [Full Text]